Co-Diagnostics, Inc. CODX

Company Overview

Co-Diagnostics, Inc. is a molecular diagnostics company focused on the development, manufacture, and commercialization of PCR-based diagnostic tests and related technologies. The company operates primarily in the in vitro diagnostics and life sciences industries, with an emphasis on infectious disease detection, genetic testing applications, and molecular laboratory solutions. Its core business centers on the design and sale of diagnostic reagents, testing platforms, and associated laboratory products used by hospitals, laboratories, public health agencies, and research institutions. Revenue has historically been driven by sales of COVID-19 diagnostic tests, molecular testing reagents, and related laboratory consumables, although the company has continued expanding into broader infectious disease and multiplex testing applications.

Co-Diagnostics is known for its proprietary CoPrimer technology platform, which is designed to improve PCR assay specificity and multiplexing capability while reducing the likelihood of nonspecific amplification. The company was founded in 2013 and is headquartered in Salt Lake City, Utah. During the COVID-19 pandemic, Co-Diagnostics experienced rapid global expansion due to demand for SARS-CoV-2 PCR tests authorized in multiple international markets. Since then, the company has focused on diversifying its product portfolio beyond pandemic-related testing into respiratory panels, vector-borne diseases, and point-of-care molecular diagnostics.